Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Sep;90(9):956-60.
doi: 10.1136/adc.2004.068890.

Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease

K Størdal  1 , G B Johannesdottir, B S Bentsen, P K Knudsen, K C L Carlsen, O Closs, M Handeland, H K Holm, L Sandvik
Affiliations
Clinical Trial

Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease

K Størdal et al. Arch Dis Child. 2005 Sep.

Abstract

Background: Epidemiological studies have shown an association between gastro-oesophageal reflux disease (GORD) and asthma, and oesophageal acid perfusion may cause bronchial constriction. However, no causative relation has been proven.

Aim: To assess whether acid suppression would lead to reduced asthma symptoms in children with concomitant asthma and GORD.

Methods: Thirty eight children (mean age 10.8 years, range 7.2-16.8; 29 males) with asthma and a reflux index > or =5.0 assessed by 24 hour oesophageal pH monitoring were randomised to 12 weeks of treatment with omeprazole 20 mg daily or placebo. The groups were similar in age, gender, mean reflux index, and asthma severity. Primary endpoints were asthma symptoms (daytime wheeze, symptoms at night, in the morning, and during exercise) and quality of life (PAQLQ). Secondary endpoints were changes in lung function and the use of short acting bronchodilators. At the end of the study a repeated pH study was performed to confirm the efficacy of acid suppression.

Results: The change in total symptom score did not differ significantly between the omeprazole and the placebo group, and decreased by 1.28 (95% CI -0.1 to 2.65) and 1.28 (95% CI -0.72 to 3.27) respectively. The PAQLQ score increased by 0.62 (95% CI 0.29 to 0.95) in the omeprazole group compared to 0.50 (95% CI 0.29 to 0.70) in the placebo group. Change in lung function and use of short acting bronchodilators were similar in the groups. The acid suppression was adequate (reflux index <5.0) under omeprazole treatment.

Conclusion: Omeprazole treatment did not improve asthma symptoms or lung function in children with asthma and GORD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of patients through the study.
See this image and copyright information in PMC

References

    1. Chest. 1999 Nov;116(5):1257-64 - PubMed
    1. Am J Gastroenterol. 1998 Jul;93(7):1060-3 - PubMed
    1. Digestion. 2000;61(1):6-13 - PubMed
    1. Clin Exp Allergy. 2000 Jun;30 Suppl 1:6-10 - PubMed
    1. Am J Respir Crit Care Med. 2000 Jul;162(1):34-9 - PubMed

Publication types